Skip to main content

Decheng Capital — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

51
Companies
$1.9B
Total invested
$49.7M
Avg. check
12
Industries
Biotechnology 20Health Care 16Medical 9Biopharma 6Pharmaceutical 5Oncology 4+6 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 124 of 51
ACELYRIN
September 2022

ACELYRIN is a biopharma company that identifies, acquires, and accelerates the development and commercialization of life-changing therapies.

Biopharma · Los Angeles$300.0M Series C
Shape Therapeutics
July 2026

A biotechnology company developing RNA technologies to shape the future of gene therapy

Biotechnology · Seattle$112.0M Grant
Watchmaker Genomics
June 2022

Watchmaker Genomics is a biotechnology company that focuses on breakthrough applications for reading, writing, and editing DNA.

Biotechnology · Boulder$40.0M Series A
Everest Medicines
May 2026

Everest Medicines is dedicated to its mission of developing and commercializing novel transformative pharmaceutical therapies for patients.

Biotechnology · New York$6.8M Post-IPO Secondary
Whitehawk Therapeutics
May 2026

Whitehawk Therapeutics, a clinical-stage oncology therapeutics firm, applies cutting-edge technologies to well-established tumor biology.

Biopharma · Pacific Palisades$87.5M Post-IPO Equity
Adela
April 2026

Adela creates develops technologies centered around detecting high-risk conditions like cancer through routine blood tests.

Biotechnology · Foster City$5.0M Convertible Note
Polares Medical
March 2026

Polares medical is a medical device company with a novel device for treating mitral valve regurgitation.

Health Care · Palo Alto$50.0M Series C
Equillium
March 2026

Equillium is a biotechnology company that develops products for autoimmune and inflammatory disorders with an unmet medical need.

Biopharma · La Jolla$35.0M Post-IPO Equity
ImmPACT Bio
February 2024

ImmPACT Bio USA is developing novel cell therapies for treating cancer.

Biotechnology · Camarillo$8.0M Grant
Nalu Medical
September 2025

Nalu Medical is a medical technology company that offers neurostimulation system designed to treat chronic nerve pain.

Health Care · Carlsbad$50.0M Venture - Series Unknown
Solve Therapeutics
December 2024

Solve Therapeutics is a biopharmaceutical company that develops Antibody Drug Conjugate and Bispecific Therapeutics.

Biopharma · Belmont$50.4M Venture - Series Unknown
Aardvark Therapeutics
May 2024

Aardvark Therapeutics specializes in small molecule therapeutics for obesity and rare genetic metabolic disorders.

Biotechnology · San Diego$85.0M Series C
LevitasBio
March 2024

LevitasBio is advancing science and human health by providing researchers with a new and powerful method of cellular analysis.

Analytics · San Francisco$11.8M Venture - Series Unknown
Firefly Bio
February 2024

Firefly Bio specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders.

Biotechnology · San Francisco$94.0M Series A
PackGene Biotech
December 2023

PackGene Biotech provides CRO/CDMO services for gene therapy and cell therapy researchers and developers.

Biotechnology · Houston$14.1M Series C
VintaBio
April 2023

VintaBio is a life sciences company that offers cell and gene therapy manufacturing services.

Biotechnology · Philadelphia$64.0M Venture - Series Unknown
Terns Pharmaceuticals
December 2025

Terns Pharmaceuticals develops small-molecule therapies for chronic diseases including cancer, metabolic disorders, and liver conditions.

Biotechnology · Foster City$650.0M Post-IPO Equity
Apexigen
January 2023

Apexigen is a clinical-stage biopharmaceutical company focused on discovering and developing a new antibody therapeutics for oncology.

Biopharma · San Carlos$2.8M Post-IPO Equity
Ottimo Pharma
December 2024

Ottimo Pharma develops innovative cancer therapies using PD1-VEGFR2 antibodies.

Biotechnology · Sandwich$140.0M Series A
CG Oncology
December 2024

CG Oncology is a clinical-stage biopharmaceutical company focused on the development of oncolytic immunotherapies to combat cancer.

Biotechnology · Irvine$238.0M Post-IPO Equity
Alpine Immune Sciences
November 2023

Alpine Immune Sciences is an immunotherapy company focused on developing treatments for autoimmune and inflammatory diseases.

Biotechnology · Seattle$150.0M Post-IPO Equity
Excellergy
October 2025

Excellergy develops immunology-based therapies focused on treating allergic diseases through novel biologic drug candidates.

Biotechnology · Palo Alto$70.0M Series A
Xtremity
October 2022

Xtremity develops a medical device to offer better connection sockets for prosthetics.

Health Care · Denver$8.1M Series B
Phrontline Biopharma
November 2025

Phrontline Biopharma develops biopharmaceutical products to treat cancer through innovative antibody-drug conjugate technology.

Biopharma · Shanghai$60.0M Seed

Where Decheng Capital invests

Biotechnology20
Health Care16
Medical9
Biopharma6
Pharmaceutical5
Oncology4

About Decheng Capital's portfolio

How many companies has Decheng Capital invested in?

Decheng Capital has invested in 51 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Decheng Capital invest in?

Decheng Capital's top investment sectors include Biotechnology, Health Care, Medical, Biopharma, Pharmaceutical. The firm invests across 12 different industry categories.

What is Decheng Capital's largest investment?

Among tracked funding rounds, Terns Pharmaceuticals received $650.0M in a Post-IPO Equity round. Decheng Capital's total known invested capital is $1.9B.

What is the average investment size for Decheng Capital?

Decheng Capital's average investment size is $49.7M across its portfolio of 51 companies.

What are Decheng Capital's most recent investments?

Recent Decheng Capital portfolio additions include ACELYRIN, Shape Therapeutics, Watchmaker Genomics, Everest Medicines, Whitehawk Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 51 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →